Long-term results of Nivolumab + Cabozantinib in RCC

Published Date: 08 Mar 2023

The combination of first-line nivolumab and cabozantinib continues to outperform sunitinib in the treatment of patients with advanced renal cell carcinoma (RCC).

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Mutation Clearance After Transplant Linked to Better Outcomes in Myelofibrosis

2.

Immunotherapy in Head and Neck Cancer After Failure of Definitive Therapy.

3.

Teenagers Frequently Use Delta-8 THC; New Drug-Coated Balloon Treats Blocked Stents.

4.

Finding a clue to the origin of treatment-resistant leukemia in kids

5.

Novel biomarker has potential for predicting and treating skin cancer metastasis


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot